Program 1 Clinical stage
Acute Ischemic Stroke (AIS)
After successful preclinical development, ApTOLL’s First-in-Human clinical trial (Phase I) to determine the safety profile in healthy volunteers was successfully completed.
A Phase Ib/IIa trial (clinical Proof-of-Concept) to assess the safety and neuroprotective effect of ApTOLL in a limited number of acute ischemic stroke patients is planned to start in 2020.
Program 2 Preclinical stage
Intracerebral Hemorrhage (ICH)
Preclinical studies are being conducted to confirm ApTOLL’s neuroprotective effect in intracerebral hemorrhage. Experimental models of intracerebral hemorrhage are being used to evaluate the impact of ApTOLL treatment on short- and long-term disease progression.
Program 3 Preclinical stage
Myocardial Infarction (MI)
Preclinical studies are being conducted to confirm ApTOLL’s cardioprotective effect in acute myocardial infarction. These studies are evaluating the impact of ApTOLL administration in infarct volume and cardiac remodeling using an ischemia-reperfusion model in different animal species.
Program 4 Preclinical stage
Multiple Sclerosis (MS)
Preclinical studies are being conducted to determine ApTOLL’s neuroprotective and regenerative effect in multiple sclerosis. These studies are evaluating the immunomodulatory and remyelinating effect of ApTOLL in different experimental models of multiple sclerosis.